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Background: Class IC antiarrhythmic drugs, used to prevent paroxysmal atrial tachyarrhythmias (ATs), are
well known to effectively unmask the electrocardiogram (ECG) pattern of Brugada syndrome. We used these
drugs to investigate the prevalence and prognosis of patients with lone and paroxysmal ATs and Brugada-
type ECGs.
Methods and results: We enrolled 702 consecutive patients who were given class IC antiarrhythmic drugs
(pilsicainide or propafenone) to inhibit paroxysmal ATs. We analyzed 12-lead ECGs before and after drug
administration using a computerized ECG system. A Brugada-type ECG was deﬁned as a coved pattern of ST
segment elevation (40.2 mV) in leads V1V2. No patients had risk-stratifying factors of the syndrome. Forty-
four patients (6.3%) had signiﬁcant ST-segment elevation in leads V1V2 after drug administration. Among
these patients, a coved ECG pattern was observed in 10 (1.4%). The use of pilsicainide (n¼9) was signiﬁcantly
(P¼0.02) greater than that of propafenone (n¼1). During the follow-up period of 85719 months, none of
the 10 patients had ventricular tachyarrhythmias.
Conclusions: Manifestation of Brugada-type ECGs by class IC antiarrhythmic drugs is neither rare nor serious
in patients with lone and paroxysmal ATs but without risk-stratifying factors for the syndrome.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Brugada syndrome [1,2] is an arrhythmogenic disorder associated
with a high risk of sudden cardiac death in individuals with struc-
turally normal hearts. The syndrome is characterized by a coved
pattern of ST-segment elevation in electrocardiogram (ECG) leads V1
to V2. Such ECG ﬁndings have been reported to be dynamic and are
often concealed [3–8]. However, they become unmasked by intrave-
nous or oral administration of class IC antiarrhythmic drugs such asrt Rhythm Society. Published by E
ants-in-Aid (22136011 and
of Education, Culture, Sports,
Promotion Grant from Toho
to T.I.).
r Medicine, Toho University
o 143-8541, Japan.pilsicainide and propafenone [9–12]. Accordingly, temporal use of
these drugs has been introduced as an effective technique (namely,
a pharmacological challenge test) for identifying patients at risk of
Brugada syndrome and for patients with concealed forms of Brugada-
type ECGs [13,14]. However, the predictive accuracy of such drug
administration for risk stratiﬁcation remains unknown.
Class IC antiarrhythmic drugs have generally been used to manage
paroxysmal atrial tachyarrhythmias (ATs) in clinical practice and are
highly effective for preventing AT attacks [15–17]. However, there are
no available data on the prevalence and prognosis of patients with
paroxysmal AT without a history of Brugada syndrome who show
Brugada-type ECGs on use of class IC antiarrhythmic drugs.
In the present study, we determined the prevalence of a coved
Brugada-type ECG pattern using class IC antiarrhythmic drugs
in patients with paroxysmal ATs but without organic cardiac
disorders, a syncopal episode, or a familial history of sudden
death. Furthermore, we evaluated the prognosis of select patientslsevier B.V. All rights reserved.
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in a prospective follow-up study.before
V2
after
Fig. 1. Deﬁnition of Brugada-type electrocardiogram (ECG) ﬁndings. A Brugada-
type ECG was deﬁned as an ST segment elevation of 40.2 mV with a coved
pattern, measured at 40 ms after the J point in lead V1 or V2.2. Methods
2.1. Patient population
This study enrolled 702 consecutive patients who were treated
with class IC antiarrhythmic drugs to inhibit paroxysmal ATs at
our institutes between March 2002 and February 2007 (Table 1).
Patients who experienced adverse effects such as stomachache
and dyspepsia were not included in this study. The mean patient
age was 69712 years (65716 years in 407 men and 71711
years in 295 women). Of the patients, 582 had paroxysmal atrial
ﬁbrillation (83%), 106 had paroxysmal atrial ﬂutter (15%), and 14
had paroxysmal supraventricular tachycardia (2%).
No patients had either syncopal episodes or a familial history
of sudden death (risk-stratifying factors). We excluded patients
who had evidence of organic heart disease such as ischemic heart
disease or cardiomyopathy. These diagnoses were based on a
physician’s questionnaire, blood tests, 12-lead electrocardiogra-
phy, and echocardiography. Thus, all subjects were considered to
have structurally normal hearts. We also excluded patients who
showed Brugada-type ECGs (with both the coved and saddle-back
ST-segment elevation patterns) before starting medication.
This study was approved by the institutional review boards of
our institutes.
2.2. Administration of class IC antiarrhythmic drugs
Class IC antiarrhythmic drugs were administered orally to
inhibit paroxysmal ATs. The speciﬁc drugs were pilsicainide
(n¼337; 48%) and propafenone (n¼365; 52%) and were adminis-
tered at the usual dosages (150–200 mg/day and 300–450 mg/
day, respectively). Patients with characteristic Brugada-type ECGs
after drug administration were included in the follow-up study.
2.3. ECG Assessment before and after medication
We assessed the right precordial leads (V1 and V2) during sinus
rhythm on 12-lead ECGs that were recorded before and after class
IC antiarrhythmic drug administration. None of the included
patients had any documented ECG abnormalities such as a wide
QRS complex, ST-segment changes, or T-wave inversion on
12-lead ECGs immediately before taking the medication. The
12-lead ECGs were recorded 1–2 h after drug administration.
Two ECGs, recorded before and after drug administration, were
analyzed using a computerized ECG machine (Nihon Kohden, Inc.,
Tokyo, Japan). The acquired ECGs were superimposed and then
visualized on the computer screen (Fig. 1). First, the magnitudeTable 1
Characteristics of patients with lone and paroxysmal atrial
tachyarrhythmia treated with class IC antiarrhythmic drugs.
Number of patients 702
Age (years) 69712
Men 65716
Women 71711
Gender, male 407 (58%)
Atrial tachyarrhythmias
Atrial ﬁbrillation 582 (83%)
Atrial ﬂutter 106 (15%)
Supraventricular tachycardia 14 (2%)
Class IC antiarrhythmic drugs
Pilsicainide (150–200 mg/day) 337 (48%)
Propafenone (300–450 mg/day) 365 (52%)(mV) of the ST-segment elevation was automatically determined
by the machine. In this study, ST-segment elevation was deﬁned
as 40.2 mV at 40 ms after the J point in lead V1 or V2. Next, two
investigators checked whether these selections were correct and
whether the ST-segment elevation formed a coved pattern.
2.4. Follow-up study and endpoints
Follow-up data were obtained once or twice a month at our
outpatient clinics. We carefully followed-up those patients
who had shown ST-segment elevation of 40.2 mV with a coved
pattern after administration of pilsicainide or propafenone. None
of these patients were switched to the other drug because the
drug they were taking effectively inhibited the paroxysmal ATs.
The endpoints were prospectively deﬁned as sudden death, the
occurrence of ventricular tachyarrhythmia, and syncopal attacks.
2.5. Statistical analysis
Data are expressed as mean7SD. Differences in the preva-
lence of Brugada-type ECGs elicited by the 2 class IC antiarrhyth-
mic drugs were examined using the contingency chi-squared test
(Fisher’s exact test). A value of Po0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Prevalence of Brugada-type ECGs after using class IC
antiarrhythmic drugs
ST-segment elevation of 40.2 mV in lead V1 or V2 after the
administration of a class IC antiarrhythmic drug was observed in
44 (6.3%) of the 702 patients with AT (Fig. 2). Of these patients, 22
(6.5%) received pilsicainide and 22 (6.0%) received propafenone.
The prevalence did not differ between the two drugs.
Among all the patients, 10 (1.4%) showed prevalence of the
deﬁned Brugada-type ECG pattern (i.e., ST-segment elevation
with a coved pattern) (Fig. 3). Of these 10 patients, 9 (2.7%)
received pilsicainide and 1 (0.3%) received propafenone. The
prevalence of the Brugada-type ECGs after pilsicainide use was
signiﬁcantly greater than that after propafenone use (P¼0.02;
i d2003.2.5
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Fig. 2. Demonstration of ST-segment elevation of 40.2 mV in the precordial
leads. This patient had an ST-segment elevation of 40.2 mV in lead V2 but did not
show a coved pattern.
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Fig. 3. Demonstration of ST-segment elevation of 40.2 mV with a coved pattern
in the precordial leads. This patient had a coved pattern in addition to an
ST-segment elevation of 40.2 mV in lead V2.
Table 2
Prevalence of ST-segment elevation and deﬁned Brugada-type electrocardiograms
after class IC antiarrhythmic drug administration.
ST-segment
elevation of
40.2 mV
Brugada-type
electrocardiogram
with a coved pattern
Class IC antiarrhythmic drugs
(1.4%)
44/702 (6.3%) 10/702
Pilsicainide
(150–450 mg/day)
22/337 (6.5%) 9/337n
Propafenone
(300–450 mg/day)
22/365 (6.0%) 1/365 (0.3%)
n P¼0.02 compared with propafenone by a contingency chi-squared test
(Fisher’s exact test).
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(men 7; women 3). Clinical characteristics such as patient age
and gender did not differ between these patients and the entire
patient population. With regard to the type of ATs, the drugs were
used for managing paroxysmal atrial ﬁbrillation in all 10 patients.
3.2. Long-term follow-up of patients with Brugada-type ECGs
Clinical follow-up of the 10 patients with a coved Brugada-
type ECG pattern was performed once or twice a month on an
outpatient basis. These patients maintained a sinus rhythm withthe use of either pilsicainide or propafenone. The 12-lead ECGs
were recorded at different time intervals to determine the efﬁcacy
of the drugs. The ECGs recorded from lead V1 or V2 changed
dynamically after drug administration because the timing of the
recording was not standardized (Fig. 4). The ECG patterns were
dependent on the timing of the recording because this is corre-
lated with drug concentration.
During the follow-up period of 85719 months (mean period,
approximately 7 years), none of these patients experienced
sudden death, serious ventricular tachyarrhythmias, or syncopal
attacks.4. Discussion
This study is the ﬁrst to assess the prevalence and prognosis of
patients with lone and paroxysmal ATs and a typical Brugada-type
ECG pattern after class IC antiarrhythmic drug administration.
The 12-lead ECG pattern typical of Brugada syndrome is known
to be dynamic and is often concealed in high-risk groups [1].
Although its mechanism has not been fully clariﬁed, a pharmacolo-
gical challenge test using sodium channel blockers, in particular
class IC antiarrhythmic drugs, has been used to identify the
manifestation of Brugada syndrome and to identify the patients
at risk of aborted cardiac sudden death or lethal ventricular
arrhythmias [13,14]. However, the speciﬁcity and sensitivity of this
technique for risk stratiﬁcation remains unknown in patients with
no history of Brugada-type ECGs.
Class IC antiarrhythmic drugs such as pilsicainide and propa-
fenone have been used to terminate or prevent ATs, particularly
atrial ﬁbrillation [15–17]. Pilsicainide and propafenone in Japan,
and ajmaline in Europe, are commonly used as ﬁrst-line drugs for
antiarrhythmic therapy [13]. We often encounter Brugada-type
ECG changes after drug therapy in daily clinical practice, but no
epidemiological data have been reported.
In the present study, we assessed the prevalence of Brugada-
type ECGs after administration of class IC antiarrhythmic drugs in
patients with paroxysmal ATs but without any risk-stratifying
factors for the syndrome, such as syncopal episodes or a familial
history of sudden death. We found that 6.3% of all the patients
had a signiﬁcant ST-segment elevation and that 1.4% of the
patients showed a typical Brugada-type ECG form with a coved
pattern after drug administration. The prevalence of Brugada-type
ECGs showing a coved pattern in lead V1 or V2 among healthy
populations ranges from 0.05% to 0.27% in Japan [21–24] and
from 0% to 0.1% in foreign countries [18–20,25]. The prevalence of
1.4% in our study was at least 10-fold greater than the mean
prevalence (0.1–0.2%) of Brugada-type ECGs in the healthy Japa-
nese population. This may suggest that lone AT patients are more
susceptible to Brugada syndrome than healthy subjects. In fact,
on drugbefore drug
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Fig. 4. Electrocardiograms (ECGs) during long-term follow-up. This patient had an ST-segment elevation of 40.2 mV with a coved pattern in the precordial leads after
administration of a class IC antiarrhythmic drug (pilsicainide). The ECGs changed dynamically after drug use because the recording time was not standardized.
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reported to have ATs [26–28].
None of the 10 patients with a coved Brugada-type ECG
pattern experienced serious adverse events during the mean
follow-up period of 7 years. In patients with lone AT but without
a history of Brugada-type ECGs or risk-stratifying factors for the
syndrome, continuous administration of class IC antiarrhythmic
drugs did not seem to be a problem despite signiﬁcant ECG
changes after the administration of medication.
4.1. Study limitations
In the present study, we did not assess noninvasive risk
stratiﬁcation markers such as late potentials on signal-averaged
ECGs [29], a full stomach test [30], or genetic analysis [14].
Thus, we do not know the association, if any, between AT and
these markers.
The AT patients enrolled in this study were older than the
general population at risk for sudden cardiac death due to
Brugada syndrome. Assessment of the prognostic value of the
manifestation of Brugada-type ECGs after class IC antiarrhythmic
drug administration in younger patients with AT may be
necessary.5. Conclusions
The manifestation of Brugada-type ECGs after class IC antiar-
rhythmic drug administration is not rare in patients with lone and
paroxysmal ATs. Continuous administration of such drugs may
be feasible for AT management if the patients do not have any
risk-stratifying factors for the syndrome.Conﬂict of interest
No potential conﬂict of interest declared.
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